NCT00337675View on ClinicalTrials.gov

Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,771

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Asthma
Interventions
DRUG

montelukast sodium

Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.

DRUG

Comparator: Placebo (unspecified)

Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.

DRUG

montelukast sodium

Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00337675 - Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED) | Biotech Hunter | Biotech Hunter